Deucravacitinib

Uses

Product Name: Deucravacitinib
CAS No.: 1609392-27-9
Chemical Name: Deucravacitinib
Synonyms: Deucravacitinib;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Tyk2-IN-4;Decavatinib;Deucravacitinb;BMS-986165 API;Deuterium seletinib;BMS-986165, >98% (HPLC);Deucravacitinib (TYK2-IN-4;Deucravacitinib(BMS986165)
CBNumber: CB74808663
Molecular Formula: C20H22N8O3
Formula Weight: 422.45
MOL File: 1609392-27-9.mol

More

Less

Deucravacitinib Property

storage temp.: Store at -20°C
solubility: DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
form: A crystalline solid
color: Off-white to light yellow
InChIKey: BZZKEPGENYLQSC-UHFFFAOYSA-N
SMILES: O(C1C(=CC=CC=1C1=NN(C)C=N1)NC1C=C(NC(C2CC2)=O)N=NC=1C(=O)NC([H])([H])[H])C

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H372Causes damage to organs through prolonged or repeated exposure

Precautionary statements

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P314Get medical advice/attention if you feel unwell.

P501Dispose of contents/container to..…

More

Less

N-Bromosuccinimide Price

ChemScene

Product number: CS-0065044
Product name: BMS-986165
Purity: 99.79%
Packaging: 10mg
Price: $350
Updated: 2021/12/16

ChemScene

Product number: CS-0065044
Product name: BMS-986165
Purity: 99.79%
Packaging: 50mg
Price: $850
Updated: 2021/12/16

DC Chemicals

Product number: DC12174
Product name: Deucravacitinib(BMS986165)
Purity: >98%
Packaging: 250mg
Price: $1100
Updated: 2021/12/16

DC Chemicals

Product number: DC12174
Product name: Deucravacitinib(BMS986165)
Purity: >98%
Packaging: 1g
Price: $2200
Updated: 2021/12/16

Crysdot

Product number: CD31005021
Product name: 6-[(Cyclopropylcarbonyl)amino]-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methyl-3-pyridazinecarboxamide
Purity: 98%
Packaging: 5mg
Price: $450
Updated: 2021/12/16

More

Less

Deucravacitinib Chemical Properties,Usage,Production

Uses

BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.

Description

Deucravacitinib (trade name Sotykto) is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disease characterized by the formation of red patches and scaling on the skin. Discovered by Bristol Myers Squibb (BMS), deuterated colestitinib, also known as BMS-986165, is the first JAK inhibitor containing deuterium and the first approved selective TYK2 inhibitor, showing more than 50,000-fold selectivity over JAK1, JAK2 and JAK3.

Uses

Deucravacitinib is a tyrosine kinase 2 inhibitor which can be useful in the treatment of systemic lupus erythematosus.

General Description

Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.

Pharmacokinetics

The crystalline free base form of deucravacitinib exhibited poor aqueous solubility (5.2 μg/mL), which was still acceptable for preclinical studies. It showed moderate half-lives of 4?5 h across species (mouse, dog, and monkey). Excellent exposures and high bioavailability (F > 85%) in mice, dogs, and monkeys were obtained from oral pharmacokinetic studies at a 10 mpk dose. Following oral administration of deucravacitinib, the major metabolite in human plasma was the cyclopropyl carboxamide hydrolytic cleavage product 4 (6-amino-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylpyridazine-3-carboxamide).

Synthesis

Lewis acid-mediated SNAr reaction of pyridazine 15.12 and aniline 15.7 gave 15.13 in 95% yield with excellent regioselectivity (∼185:1 15.13:15.14). Although an unconventional compound, 15.13 was isolated as a Zn-dicarboxylate due to its good solubility, ease of crystallization and isolation. The aryl pyridazine 15.13 then formed a C-N bond with amide 15.15 under Pd catalysis to afford the penultimate carboxylate 15.16 in 94% yield. Trideuterated methylamides were generated under standard amide coupling conditions. Deucravacitinib was prepared in 75% yield by crystallization in NMP and i-PrOH.

IC 50

Tyk2 JH2: 0.2 nM (IC₅₀); JAK1 JH2: 1 nM (IC₅₀); IL-12; IL-23

Deucravacitinib Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Deucravacitinib Suppliers

China 216 India 2 United States 7 Global 225

Jinan XuanDe Chemical Co., Ltd.

Tel: 0531-88803958 18866891188
Fax: 0531-82777287
Email: 18853169188@163.com
Country: China
ProdList: 193
Advantage: 58

ShangHai Caerulum Pharma Discovery Co., Ltd.

Tel: 18149758185
Email: sales-cpd@caerulumpharma.com
Country: China
ProdList: 3506
Advantage: 58

Shandong utilizing biological technology co., LTD

Tel: 15966937598
Fax: 3407640895 3071519937
Email: 3407650895@qq.com
Country: China
ProdList: 2274
Advantage: 58

Shanghai Hope Chem Co., Ltd.，

Tel: +21-18501659228 18501659228
Fax: sales@hope-chem.com
Email: info@hope-chem.com
Country: China
ProdList: 474
Advantage: 55

Cangzhou Kangrui Medical Technology Co., LTD

Tel: 18632776803
Email: 355803330@qq.com
Country: China
ProdList: 630
Advantage: 58

Jinan Dexinjia Bio&Tech Co., Ltd

Tel: 0531-82371986 15269101859
Fax: 0531-82375893
Email: 3276840968@qq.com
Country: China
ProdList: 1604
Advantage: 58

Cangzhou Enke Pharma Tech Co.,ltd.

Tel: 0317-5106596 15533709196
Email: 1154424302@qq.com
Country: China
ProdList: 2262
Advantage: 58

CHANGZHOU PHARMACEUTICAL FACTORY

Tel: 519-88821493 18915891730
Email: shm@czpharma.com
Country: China
ProdList: 170
Advantage: 58

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6003
Advantage: 61

Energy Chemical

Tel: 021-021-58432009 400-005-6266
Fax: 021-58436166
Email: sales8178@energy-chemical.com
Country: China
ProdList: 44801
Advantage: 61

More

Less

View Lastest Price from Deucravacitinib manufacturers

Moxin Chemicals

Product: Deucravacitinib Impurity 1609392-27-9
Price: US $0.00-0.00/mg
Min. Order: 10mg
Purity: 99%+ HPLC
Supply Ability: 1000
Release date: 2025-06-06

Cangzhou Kangrui Pharma Tech Co. Ltd.,

Product: Deucravacitinib 1609392-27-9
Price: US $0.00-0.00/g
Min. Order: 10g
Purity: 98%
Supply Ability: 5kgs
Release date: 2024-12-02

Zhengzhou Anbu Chem Co.,Ltd

Product: BMS-986165 1609392-27-9
Price: US $0.00/KG
Min. Order: 0.1KG
Purity: 98%
Supply Ability: 1000KGS
Release date: 2023-07-14

1609392-27-9, DeucravacitinibRelated Search:

Tyk2-IN-4

TYK2-IN-4;BMS986165;BMS-986165;BMS 986165

6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

Deucravacitinib

Deucravacitinib(BMS986165)

Deucravacitinib (TYK2-IN-4

6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide

DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib

Janus kinase,inhibit,JAK,Interleukin Related,Interferon-alpha/beta receptor,BMS 986165,Interferon-α/β receptor,IFNAR,Inhibitor,Deucravacitinib,BMS986165

6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamide

6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide

Deucravacitinb

BMS-986165 API

BMS-986165, >98% (HPLC)

Deucravacitinib, 10 mM in DMSO

Decavatinib

Deuterium seletinib

6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide - [AC79859]

6-Cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide

1609392-27-9

API

APIS

API